Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

Medulloblastoma, the most common malignancy of childhood, was originally shown to be sensitive to cyclophosphamide in 1981. We have used combined laboratory and clinical investigations to demonstrate the synergy of cyclophosphamide and vincristine in the treatment of this tumor, the therapeutic gain associated with escalation of the dosage of cyclophosphamide, the consequence of and mechanisms underlying resistance of medulloblastoma to cyclophosphamide, the emerging importance of the neuraxis as a site of relapse of medulloblastoma, and newer approaches, including intrathecal 4-hydroperoxycyclophosphamide and busulfan, to treat neuraxis disease. These studies serve as a paradigm for laboratory-clinical translational research.
AuthorsH S Friedman, S H Bigner, D D Bigner
JournalJournal of neuro-oncology (J Neurooncol) Vol. 24 Issue 1 Pg. 103-8 ( 1995) ISSN: 0167-594X [Print] NETHERLANDS
PMID8523066 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Cyclophosphamide
  • Animals
  • Clinical Laboratory Techniques
  • Clinical Trials as Topic
  • Cyclophosphamide (therapeutic use)
  • Drug Resistance, Neoplasm
  • Humans
  • Medulloblastoma (diagnosis, drug therapy)
  • Meningeal Neoplasms (complications, drug therapy)
  • Meningitis (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: